The first 'B' name is CR Bard (BCR), Cramer said. Although the stock is up 25% since he first suggested buying it in September 2005, Cramer believes Bard should continue on its pathway up. Bard, Cramer said, is a "primo" medical device maker. Last year, 80% of its sales came from markets where it ranks No. 1 or No. 2 in market share. In 2005, Cramer advised buying Bard as a takeover target, and on Monday Cramer recommended it the same way, saying the company is small enough to swallow. No matter what happens to the economic climate, Bard will not be affected, because it makes medical devices that people cannot live without. Bard is also sitting on half a billion dollars in cash, which it can use to increase its dividend or purchase companies of its own, he said.

The second stock Cramer suggested viewers purchase as part of his "Three B's Portfolio" was Becton Dickinson (BDX). It is a "safe" medical device and diagnostics company that makes needles "of all kinds." And with two "smart" acquisitions it recently made, Becton now has an "ultrafast" test to detect drug-resistant staph infections, Cramer said. Although this play is up 31% since last July, when Cramer told people to think about buying it, Becton has more room to run, he said. Last week, the company reported a great quarter with raised guidance.

The third 'B' pick Cramer said he likes is Baxter International (BAX), which unlike Boston Scientific (BSX) is best of breed. However, he said he wouldn't buy Baxter until it pulls back a bit. Though Baxter has outperformed Boston Scientific as well as Becton Dickinson and CR Bard, that is not what makes it best of breed, Cramer explained. Instead, a lot of what distinguishes Baxter is the diversity of its products, he said. Its broad range of products and services makes it less speculative and more reliable than BSX. Also, Cramer said he didn't like Boston Scientific's recent quarter "one bit." He understands that people might be attracted to Boston Scientific because it's cheaper, but they should understand that it's cheaper for a good reason, Cramer said.